Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Stressor-Focused Therapy for Emotional Processing in Adjustment Disorder (STEP)

14 de novembro de 2026 atualizado por: Rahel Bachem

STEP - Stressor-focused Therapy for Emotional Processing in ICD-11 Adjustment Disorder: A Randomised Waitlist-Controlled Trial

This randomized controlled trial evaluates the efficacy of STEP, a brief 12-session psychotherapy for adults with ICD-11 Adjustment Disorder (AjD). STEP is a manualized, CBT-based, event-focused intervention designed to reduce Adjustment Disorder symptoms and support adaptive emotional processing and coping. Participants in the waitlist control group will receive STEP after the 12-week waiting period. Outcomes will be assessed at baseline, post-treatment, and at a 3-month follow-up. The primary outcome is Adjustment Disorder symptom severity. Secondary outcomes include perceived stress, depression, anxiety, well-being, and experiential avoidance.

Visão geral do estudo

Status

Ainda não está recrutando

Intervenção / Tratamento

Descrição detalhada

Adjustment disorder (AjD) is characterised in ICD-11 by two core symptom clusters: preoccupation with the stressor and failure to adapt. Although adjustment disorder is frequently diagnosed in clinical practice, evidence for disorder-specific psychological treatments based on the ICD-11 conceptualisation remains limited.

STEP (Stressor-focused Therapy for Emotional Processing) was developed to address these core symptoms through a structured, event-focused cognitive-behavioural approach. The treatment is based on the conceptualisation of adjustment disorder as a stress-response syndrome, in which persistent preoccupation with a stressful life event and avoidance of associated memories, thoughts, and emotions may contribute to symptom maintenance.

Drawing on established cognitive-behavioural and trauma-focused treatment principles, STEP integrates psychoeducation, individual case formulation, emotional awareness and regulation, event-focused imaginal exposure, cognitive restructuring, resource activation, and adaptive coping strategies. A central component is the guided emotional processing of distressing life events and emotionally salient moments associated with the stressor. The intervention aims to reduce maladaptive avoidance and preoccupation, facilitate emotional processing, and support adaptation to changed life circumstances.

This randomised waitlist-controlled trial evaluates the efficacy of STEP in adults diagnosed with ICD-11 adjustment disorder. The primary hypothesis is that participants receiving STEP will demonstrate greater reductions in adjustment disorder symptoms than participants assigned to the waitlist condition. Secondary objectives include examining changes in psychological distress, experiential avoidance, and subjective well-being, as well as evaluating treatment feasibility and acceptability.

The study is expected to contribute to the development of targeted, evidence-based psychotherapeutic interventions for adjustment disorder.

Tipo de estudo

Intervencional

Inscrição (Estimado)

70

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Rahel Bachem, Prof. Dr.
  • Número de telefone: +41 58 257 35 26
  • E-mail: rahel.bachem@ost.ch

Locais de estudo

    • Canton of St. Gallen
      • Sankt Gallen, Canton of St. Gallen, Suíça, 9001
        • Competence Center for Mental Health; Eastern Switzerland University of Applied Sciences
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of ICD-11 Adjustment Disorder confirmed via structured clinical interview using the IADQ diagnostic algorithm
  • Presence of a clearly identifiable psychosocial stressor 2 weeks to 2 years before participation
  • Sufficient German language proficiency to participate in psychotherapy and complete study assessments
  • Capacity to provide written informed consent

Exclusion Criteria:

  • Current PTSD or CPTSD meeting ICD-11 diagnostic criteria following a Criterion A traumatic event
  • Current prolonged grief disorder meeting ICD-11 diagnostic criteria
  • Lifetime history of bipolar disorder or psychotic disorder, including schizophrenia spectrum disorders
  • Severe depressive or anxiety symptoms clearly predating the identified stressor and judged to better account for the current clinical presentation
  • Another severe mental disorder that would interfere with participation in psychotherapy or better explain the presenting symptoms
  • Acute suicidality requiring immediate crisis intervention
  • Ongoing psychotherapy

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: STEP Intervention Group

Participants assigned to the intervention group receive 12 weekly sessions of the STEP psychotherapy intervention after completion of the baseline assessment.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

Outro: Waitlist Control Group

Participants assigned to the waitlist control group do not receive the STEP intervention during the 12-week waiting period. After completion of the waiting period, participants receive the STEP intervention.

STEP is a brief, manualized, 12-session CBT-based psychotherapy specifically developed for ICD-11 Adjustment Disorder (AjD). It follows a staged, event-focused approach targeting the core symptom clusters of preoccupation and failure to adapt. Treatment components include psychoeducation and individualized case conceptualization, emotional awareness and regulation skills, stressor-focused imaginal exposure and emotional processing, cognitive and emotional reprocessing of stressor-related meanings, strengthening of personal resources and adaptive coping strategies, and relapse prevention.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Adjustment Disorder Symptom Severity at Post-Treatment
Prazo: Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)

Adjustment disorder symptom severity is assessed using the International Adjustment Disorder Questionnaire (IADQ). The primary outcome is the sum of six symptom items (Items 1-6), covering preoccupation with the stressor and failure to adapt. Each item is rated from 0 to 4, resulting in a total score ranging from 0 to 24, with higher scores indicating greater symptom severity. Scores at T1 will be compared between groups, adjusting for baseline scores.

Week 12-14 after baseline (T1; post-treatment in the immediate intervention group and post-waiting period in the control group)
Depressive Symptom Severity
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Depression Questionnaire (IDQ), measuring depressive symptoms according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Anxiety Symptom Severity
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the International Anxiety Questionnaire (IAQ), measuring symptoms of generalized anxiety according to ICD-11.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Perceived Stress
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the 10-item Perceived Stress Scale (PSS-10), measuring the perceived level of stress.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Subjective Well-Being
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the World Health Organization-Five Well-Being Index (WHO-5), measuring subjective psychological well-being.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Experiential Avoidance
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Brief Experiential Avoidance Questionnaire (BEAQ), measuring the tendency to avoid unwanted internal experiences.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Adjustment Disorder Diagnostic Status
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed through a structured clinical interview evaluating the presence or absence of ICD-11 adjustment disorder and diagnostic remission.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).
Treatment Credibility and Expectancy
Prazo: Immediately after STEP Session 1

Assessed using the Credibility/Expectancy Questionnaire (CEQ), measuring treatment credibility and expected improvement.

Immediately after STEP Session 1
Treatment Acceptability and Feasibility
Prazo: Immediately after completion of the 12-session STEP treatment

Assessed using the Treatment Feedback and Adherence questionnaire (TFA), evaluating participants' experiences with STEP.

Immediately after completion of the 12-session STEP treatment
Event-Focused Repetitive Thoughts
Prazo: Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Assessed using the Event-focused Repetitive Thoughts Questionnaire (ERTQ), measuring repetitive thoughts related to stressful life events.

Baseline (T0), Week 12-14 (T1), and 3 months after treatment completion (T2).

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de janeiro de 2027

Conclusão Primária (Estimado)

1 de março de 2029

Conclusão do estudo (Estimado)

1 de maio de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

14 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • STEP_PILOTSTUDY
  • PT0041_222855 (Número de outro subsídio/financiamento: Swiss National Science Foundation - SNSF)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

A fully anonymized individual participant dataset will be made available in a publicly accessible scientific repository (e.g., OSF) following publication of the primary study results. All direct identifiers will be removed, and indirect identifiers will be minimized to prevent re-identification. No identifiable or coded participant data will be shared.

Prazo de Compartilhamento de IPD

The anonymized individual participant dataset will become publicly available following publication of the primary study results. The dataset will remain accessible for as long as it is maintained in the selected public scientific data repository.

Critérios de acesso de compartilhamento IPD

The fully anonymized dataset will be publicly accessible to researchers and other interested users through an open scientific data repository, such as the Open Science Framework (OSF), without an individual access request. The shared dataset will contain numerical questionnaire data and broadly categorized demographic information. Free-text descriptions, exact age, geographical information, direct identifiers, and coded participant data will not be made publicly available. A data dictionary will accompany the dataset.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever